October 23, 2012
CarolinaEast Health System Not Recipient Of Contaminated Drug
Officials Assure Patient Safety
In response to an outbreak of fungal meningitis in patients who received potentially contaminated steroid medication, officials at CarolinaEast Health System have taken all necessary steps to protect their patients and assure there has been no exposure to this drug by patients of CarolinaEast.
The Food and Drug Administration, the Centers for Disease Control and the North Carolina Division of Public Health are investigating an outbreak of fungal meningitis in patients receiving injections for back pain of the drug methylprednisolone acetate prepared by the New England Compounding Center (NECC) in Framingham, Massachusetts. Three specific lot numbers were recalled in late September and as a precaution, all other medications prepared by NECC were recalled in early October.
“CarolinaEast did not receive any of the potentially contaminated injectable steroid,” said Megan McGarvey, Director, Public Relations. While CarolinaEast did have one injectable medication prepared by NECC included in its inventory, this drug has not been identified as a potentially contaminated medication and is used in a completely different treatment protocol.
“Prior to the mandatory recall of the medications, we voluntarily pulled all NECC stock from our inventory and proactively had it tested in our laboratory. We are notifying all of our patients who have received any injectable medication from NECC,” said McGarvey. “We want our patients to know that their safety is our leading concern and that if they have any questions, they should contact their health care provider.”
Read Patient Notice Here